Evaluation of BCL-6, CD10, CD138 and MUM-1 Expression in Diffuse Large B-Cell Lymphoma patients: CD138 is a Marker of Poor Prognosis |
Bodoor, Khaldon
(Department of Applied Biology, Faculty of Science and Arts, Jordan University of Science and Technology)
Matalka, Ismail (Department of Pathology, Jordan University of Science and Technology) Hayajneh, Rami (Department of Applied Biology, Faculty of Science and Arts, Jordan University of Science and Technology) Haddad, Yazan (Department of Applied Biology, Faculty of Science and Arts, Jordan University of Science and Technology) Gharaibeh, Waleed (Department of Biology, University of Jordan) |
1 | Fabiani B, Delmer A, Lepage E, et al (2004). CD10 expression in diffuse large B-cell lymphomas does not influence survival. Virchows Arch, 445, 545-51. DOI |
2 | Groves FD, Linet MS, Travis LB, et al (2000). Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst, 92, 1240-51. DOI |
3 | Hans CP, Weisenburger DD, Greiner TC, et al (2004). Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, 275-82. DOI |
4 | Harada S, Suzuki R, Uehira K, et al (1999). Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes. Leukemia, 13, 1441-7. DOI |
5 | Magomedova AU, Vorob'ev AI (2008). International prognostic index in diffuse B large cell lymphosarcoma. Ter Arkh, 80, 71-6. |
6 | Jourdan M, Ferlin M, Legouffe E, et al (1998). The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol, 100, 637-46. DOI |
7 | Kaplan EL, Meier P (1958). Nonparametric estimation from incomplete observations. J Amer Statist Assoc, 53, 457-81. DOI |
8 | Lossos IS, Jones CD, Warnke R, et al (2001). Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood, 98, 945-51. DOI ScienceOn |
9 | Lossos IS, Levy R (2003). Diffuse large B-cell lymphoma: insights gained from gene expression profiling. Int J Hematol, 77, 321-9. DOI |
10 | Lossos IS, Morgensztern D (2006). Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol, 24, 995-1007. DOI |
11 | Mann HB, Whitney DR (1947). On a test of whether one of two random variables is stochastically larger than the other. Annals of Mathematical Statistics, 18, 50-60. DOI ScienceOn |
12 | Braaten KM, Betensky RA, De Leval L, et al (2003). BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res, 9, 1063-9. |
13 | Alizadeh AA, Eisen MB, Davis RE, et al (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403, 503-11. DOI ScienceOn |
14 | Barrans SL, O'Connor SJ, Evans PA, et al (2002). Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol, 117, 322-32. DOI |
15 | Berglund M, Thunberg U, Amini RM, et al (2005). Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol, 18, 1113-20. DOI |
16 | Colomo L, Lopez-Guillermo A, Perales M, et al (2003). Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood, 101, 78-84. DOI ScienceOn |
17 | Breslow N A (1970). Generalized kruskal-wallis test for comparing K samples subject to unequal pattern of censorship. Biometrika, 57, 579-94. DOI |
18 | Camilleri-Broet S, Criniere E, Broet P, et al (2006). A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood, 107, 190-6. DOI |
19 | Chang CC, McClintock S, Cleveland RP, et al (2004). Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol, 28, 464-70. DOI |
20 | Coiffier B, Lepage E, Briere J, et al (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 346, 235-42. DOI |
21 | Phan RT, Dalla-Favera R (2004). The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature, 432, 635-9. DOI |
22 | De Paepe P, De Wolf-Peeters C (2007). Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia, 21, 37-43. DOI |
23 | Dogan A, Bagdi E, Munson P, et al (2000). CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol, 24, 846-52. DOI |
24 | Kojima Y, Tsurumi H, Goto N, et al (2006). Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome. Eur J Haematol, 76, 465-72. DOI ScienceOn |
25 | Lin CH, Kuo KT, Chuang SS, et al (2006). Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin Cancer Res, 12, 1152-6. DOI |
26 | Linderoth J, Jerkeman M, Cavallin-Stahl E, et al (2003). Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. Clin Cancer Res, 9, 722-8. |
27 | Mantel N (1966). Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep, 50, 163-70. |
28 | Muris JJ, Meijer CJ, Vos W, et al (2006). Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol, 208, 714-23. DOI |
29 | Oh YH, Park CK (2006). Prognostic evaluation of nodal diffuse large B cell lymphoma by immunohistochemical profiles with emphasis on CD138 expression as a poor prognostic factor. J Korean Med Sci, 21, 397-405. DOI |
30 | Ohshima K, Kawasaki C, Muta H, et al (2001). CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology, 39, 156-62. DOI |
31 | Hunt KE, Reichard KK (2008). Diffuse large B-cell lymphoma. Arch Pathol Lab Med, 132, 118-24. |
32 | Haarer CF, Roberts RA, Frutiger YM, et al (2006). Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival. Arch Pathol Lab Med, 130, 1819-24. |
33 | Haddadin WJ (2005). Malignant lymphoma in Jordan: a retrospective analysis of 347 cases according to the World Health Organization classification. Ann Saudi Med, 25, 398-403. |
34 | Hallermann C, Niermann C, Fischer RJ, et al (2007). New prognostic relevant factors in primary cutaneous diffuse large B-cell lymphomas. J Am Acad Dermatol, 56, 588-97. DOI |
35 | Harris NL, Jaffe ES, Stein H, et al (1994). A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 84, 1361-92. |
36 | Hoffmann C, Tiemann M, Schrader C, et al (2005). AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping. Blood, 106, 1762-9. DOI |
37 | Pileri SA, Gaidano G, Zinzani PL, et al (2003). Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol, 162, 243-53. DOI |
38 | Liu YH, Xu FP, Zhuang HG, et al (2008). Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients. Hum Pathol, 39, 875-84. DOI |
39 | Lopez Guillermo A, Montserrat E (1992). Large-cell lymphomas: the International Prognostic Index. Sangre (Barc), 37, 329-30. |
40 | Pileri SA, Dirnhofer S, Went P, et al (2002). Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology, 41, 482-509. DOI |
41 | Saez AI, Saez AJ, Artiga MJ, et al (2004). Building an outcome predictor model for diffuse large B-cell lymphoma. Am J Pathol, 164, 613-22. DOI |
42 | Sjo LD, Poulsen CB, Hansen M, et al (2007). Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups. Eur J Haematol, 79, 501-7. DOI ScienceOn |
43 | Zinzani PL, Dirnhofer S, Sabattini E, et al (2005). Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. Haematologica, 90, 341-7. |
44 | Tsuboi K, Iida S, Inagaki H, et al (2000). MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia, 14, 449-56. DOI |
45 | Tzankov A, Pehrs AC, Zimpfer A, et al (2003). Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases. J Clin Pathol, 56, 747-52. DOI |
46 | Uherova P, Ross CW, Schnitzer B, et al (2001). The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma. Am J Clin Pathol, 115, 582-8. DOI |
47 | Winter JN, Weller EA, Horning SJ, et al (2006). Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood, 107, 4207-13. DOI |
48 | Wright G, Tan B, Rosenwald A, et al (2003). A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A, 100, 9991-6. DOI ScienceOn |
49 | Xu Y, McKenna RW, Molberg KH, et al (2001). Clinicopathologic analysis of CD10+ and CD10- diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2. Am J Clin Pathol, 116, 183-90. DOI |